Immunotherapy and Targeted Therapy in Breast Cancer

Dear Colleagues,

Breast cancer remains a major cause of cancer mortality worldwide. The hope for improved survival of breast cancer patients comes from the many immunotherapeutic and targeted therapeutic strategies currently being studied. These strategies include the approved clinical use of immunotherapeutic checkpoint inhibitors for metastatic triple-negative breast cancer positive for PD-L1 expression and poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of BRCA-deficient breast cancers. Although promising, the responses to these targeted strategies are limited and additional advances in patient stratification and novel drug/target combinations are needed. We invite breast cancer studies that investigate the various aspects of immunotherapeutic and targeted therapeutic strategies. In this Topic, original research articles and reviews are welcome. Breast cancer research areas may include (but are not limited to) pre-clinical and clinical studies that investigate the various aspects of immunotherapeutic and targeted therapeutic strategies, as well novel methods of drug delivery.

Dr. Paola Marcato
Dr. Suresh Gadde
Topic Editors